| scholarly article | Q13442814 |
| P2093 | author name string | M Nomura | |
| M Kato | |||
| T Kamataki | |||
| T Yokoi | |||
| T Hagiwara | |||
| E Nagai | |||
| K Takasuna | |||
| M Hirohashi | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irinotecan | Q412197 |
| P304 | page(s) | 3752-3757 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats | |
| P478 | volume | 56 |
| Q46257516 | 5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro. |
| Q57025199 | A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients |
| Q46658581 | A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer |
| Q39139284 | A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan |
| Q38746100 | An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. |
| Q36617921 | CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues |
| Q47724378 | CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon |
| Q28203339 | Camptothecins: a review of their chemotherapeutic potential |
| Q34512245 | Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. |
| Q28079705 | Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments |
| Q41160069 | Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats |
| Q60305401 | Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective |
| Q40880283 | Clinical pharmacokinetics of irinotecan |
| Q49430799 | Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model. |
| Q37071033 | Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. |
| Q28273307 | Developing a metagenomic view of xenobiotic metabolism |
| Q37692023 | Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach |
| Q91788135 | Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis |
| Q33647853 | Effects of methimazole on the elimination of irinotecan. |
| Q38685792 | Emulating Host-Microbiome Ecosystem of Human Gastrointestinal Tract in Vitro. |
| Q35099010 | Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. |
| Q26795742 | Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q36619832 | Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects |
| Q44010193 | Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients |
| Q91992022 | Glucuronidation as a metabolic barrier against zearalenone in rat everted intestine |
| Q34924272 | Gut microbiome and anticancer immune response: really hot Sh*t! |
| Q38945423 | Gut microbiome interactions with drug metabolism, efficacy, and toxicity |
| Q28550622 | Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38 |
| Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
| Q36174270 | Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats |
| Q38102867 | Interaction between host cells and microbes in chemotherapy-induced mucositis |
| Q36384554 | Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. |
| Q36119996 | Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats |
| Q62018200 | Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers |
| Q43155338 | Irinotecan toxicity: genes or intestinal microflora? |
| Q43274557 | Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. |
| Q90655827 | Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database |
| Q91638153 | Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT-11-Induced Diarrhea in Mice |
| Q47251445 | Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats |
| Q34715481 | Metabolic pathways of the camptothecin analog AR-67 |
| Q21092513 | Metabolic reconstruction for metagenomic data and its application to the human microbiome |
| Q55094334 | Microbial markers in colorectal cancer detection and/or prognosis. |
| Q27678202 | Molecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity |
| Q35677002 | Native Electrophoresis-Coupled Activity Assays Reveal Catalytically-Active Protein Aggregates of Escherichia coli β-Glucuronidase |
| Q37732059 | Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer |
| Q33838603 | Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity |
| Q37381224 | Pharmacogenetic pathway analysis of irinotecan |
| Q35563283 | Pharmacology of intraperitoneal CPT-11 |
| Q37339628 | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer |
| Q90079768 | Predictable modulation of cancer treatment outcomes by the gut microbiota |
| Q90626013 | Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome |
| Q24633218 | Pulmonary metabolism of resveratrol: in vitro and in vivo evidence |
| Q42180635 | Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat. |
| Q37593573 | Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation |
| Q33784710 | Real-time imaging of intestinal bacterial β-glucuronidase activity by hydrolysis of a fluorescent probe |
| Q44196282 | Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats |
| Q44902594 | Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies |
| Q35742169 | Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids |
| Q44908306 | Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats |
| Q36641418 | Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. |
| Q47107453 | Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity |
| Q61443080 | Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases |
| Q90316025 | Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy |
| Q50045903 | Targeting p53-dependent stem cell loss for intestinal chemoprotection. |
| Q46207994 | The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea |
| Q35841503 | The influence of gut microbiota on drug metabolism and toxicity. |
| Q34996195 | The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018) |
| Q28538671 | The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats |
| Q37731433 | Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. |
| Q94560881 | Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics |
| Q28547375 | Tumor grafting induces changes of gut microbiota in athymic nude mice in the presence and absence of medicinal Gynostemma saponins |
| Q58608842 | β-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut |
Search more.